Hepatology: Study finds new mechanism may improve survival rates in patients with hepatocellular carcinoma

The use of programmed death receptor-1 (PD-1) to block the activation of anti-tumor immune responses has only shown benefits in a total number of patients with hepatocellular carcinoma (HCC)The combination of PD-1 blocking and antiangiogenic stompant use showed hope in some patients who responded to treatment significantly increased, but the mechanism of this interaction was not clearwe restated these clinical results using HCC of positive or induced-to-taurine modelsThe use of mouse antibodies to specifically block vascular endothelial cell receptor 2 (VEGFR-2) can significantly delay the growth of primary tumors, but can not prolong survival, and anti-PD-1 antibodies treated alone in a model of the survival advantage is smallHowever, the treatment of dual-anti-PD-1/VEGFR-2 significantly inhibits the growth of primary tumors and doubles the survival rate of both modelsJoint therapy reprogrammes the immune micro-environment by increasing cluster differentiation 8-positive (CD8-plus) cytotoxic T-cell immersion and activation, metastasis of the M1/M2 ratio of tumor-related macrophages, and reducing The T-regulating cell (Treg) and chemokine (C-C motivation) receptor 2 positive mononucleosis in HCC tissueIn these models, VEGFR-2 was selectively expressed in tumor endothelial cellsUsing a globular culture of HCC tissue, we found that after anti-VEGFR-2 blocked PD-ligand 1 expression in endothelial cells, the expression of PD-ligand 1 was induced in part by interferon-gamma-interferon expression in HCC cells in a sidewayIn addition, we found that VEGFR-2 blocking increased the expression of PD-1 in tumor-immersed CD4-plus cellsWe also found that under anti-PD-1 treatment, CD4-plus cells were treated with anti-angiogenic treatment of anti-VEGFR-2 antibodies, and CD4-plus cells promoted normalization of blood vessel formation, the results show that the double-anti-PD-1/VEGFR-2 treatment has a long-lasting vascular strengthening effect in HCC, and in the anti-PD-1 treatment resistance and anti-PD-1 treatment reactive HCC model, can overcome any kind of treatment resistance alone and improve the overall survival rate